BioMarin Acquires Amicus, Shares Surge
Update: 2025-12-23
Description
BioMarin Pharmaceutical shares surged today following news of its acquisition of Amicus Therapeutics, valued at $14.50 per share, a 33% premium. The deal adds two approved treatments for rare diseases to BioMarins portfolio, boosting its leadership position in the rare disease space. Investors are optimistic about the deals potential to accelerate revenue growth and earnings per share. Despite BioMarins year-to-date decline and its current trading price below its 52-week high, todays action suggests renewed momentum for the company as it expands its rare disease portfolio.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
